We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

DIAGNOSTICA STAGO

Offers a complete system of hemostasis instrumentation and optimized reagent kits for research, as well as for routin... read more Featured Products: More products

Download Mobile App





Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 23 Jun 2021
Print article
Image: Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021 (Photo courtesy of Diagnostica Stago)
Image: Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021 (Photo courtesy of Diagnostica Stago)
Diagnostica Stago (Asnières-sur-Seine, France), which develops and markets automated systems for blood analysis, highlighted its Max Generation family of coagulation analyzers at MEDLAB Middle East 2021.

On display at the event was the STA R Max 3, a versatile analyzer that will adapt to any type of laboratory set-up, for an equivalent performance whether used alone or integrated into an automated track. It is supported by a range of reagents offering a comprehensive menu of routine and specialized tests, ensuring effective TAT (turnaround time) management. Like its predecessor, the STA R Max 3 has an EPC module for checking sample integrity that controls fill volumes of all types of tubes and detects haemolysed, icteric and lipemic samples to ensure quality results. It requires no additional plasma volume and does not affect throughput.

The company also presented the STA Compact Max 3 which offers significant performance improvements and includes the EPC (expert pre-analytical check) module. This EPC module controls fill volumes of all types of tubes and detects haemolysed, icteric and lipemic samples, allowing the STA Compact Max 3 to check sample integrity to ensure quality results. It requires no additional plasma volume and does not affect throughput. In addition, the company highlighted the STA Satellite Max which builds on the proven strengths of the Max Generation, offering new functionalities and a user-friendly interface, making it the ideal solution for Haemostasis testing in low-volume labs. The STA Satellite Max is a Haemostasis analyzer designed specifically for “satellite” labs looking for a device that meets their needs while guaranteeing results as reliable as those obtained in large specialized laboratories.

At this year’s MEDLAB Middle East, the company showcased the STA R Max 3, a versatile analyzer that will adapt to any type of laboratory set-up, for an equivalent performance whether used alone or integrated into an automated track. It is supported by a range of reagents offering a comprehensive menu of routine and specialized tests, ensuring effective TAT (turnaround time) management.

Related Links:
Diagnostica Stago

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.